首页> 外文OA文献 >Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

【2h】

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

机译：新型口服生物可利用的小分子抑制剂RO9021对脾酪氨酸激酶（SYK）的选择性抑制会影响多种先天和适应性免疫应答：SYK抑制剂在自身免疫性疾病治疗中的意义

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Cheng Liao; Jonathan Hsu; Yong Kim; Dong-Qing Hu; Daigen Xu; Jun Zhang; Achal Pashine; John Menke; Toni Whittard; Natasha Romero; Theresa Truitt; Michelle Slade; Christine Lukacs; Johannes Hermann; Mingyan Zhou; Matthew Lucas; Satwant Narula; Julie DeMartino; Seng-Lai Tan;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy [J] . Cheng Liao, Jonathan Hsu, Yong Kim, Arthritis research & therapy. . 2013,第5期

机译：新型口服生物利用小分子抑制剂RO9021对脾酪氨酸激酶（SYK）的选择性抑制会影响多种先天和适应性免疫应答：SYK抑制剂在自身免疫性疾病治疗中的意义
2. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy [J] . Cheng Liao, Jonathan Hsu, Yong Kim, Arthritis Research . 2013,第5期

机译：新型口服生物利用小分子抑制剂RO9021对脾酪氨酸激酶（SYK）的选择性抑制会影响多种先天和适应性免疫应答：SYK抑制剂在自身免疫性疾病治疗中的意义
3. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy. [J] . Navara CS Current pharmaceutical design . 2004,第15期

机译：人类疾病中的脾酪氨酸激酶（Syk），对基于酪氨酸激酶抑制剂的疗法设计的意义。
4. CNX-774, an Irreversible, Selective and Orally Bioavailable Inhibitor of Bruton's Tyrosine Kinase: In Vitro ADME, Selectivity, and Pharmacokinetic Properties [C] . Prasoon Chaturvedi, Matthew Labenski, Erica Evans, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：CNX-774，Bruton的酪氨酸激酶的不可逆转，选择性和口服生物可利用的抑制剂：体外Adme，选择性和药代动力学性能
5. Pharmacological Characterization of TAS05567, a Potent and Selective Inhibitor of Spleen Tyrosine Kinase, in Animal Models of Inflammatory Diseases and B-cell Malignancies [D] . 林宏明 2019

机译：TAS05567，脾酪氨酸激酶的强效和选择性抑制剂，在炎症性疾病和B细胞恶性动物模型中的药理特性
6. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor RO9021 impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy [O] . Cheng Liao, Jonathan Hsu, Yong Kim, 2013

机译：新型口服生物可利用的小分子抑制剂RO9021对脾酪氨酸激酶（SYK）的选择性抑制会影响多种先天和适应性免疫应答：SYK抑制剂在自身免疫性疾病治疗中的意义
7. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy [O] . Cheng Liao, Jonathan Hsu, Yong Kim, 2013

机译：选择性抑制脾酪氨酸激酶（sYK）与新型口服生物可利用的小分子抑制剂RO9021，影响各种先天和适应性免疫反应：sYK抑制剂在自身免疫疾病治疗中的意义

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

著录项

引文网络

相似文献

相关主题

期刊订阅